IPO - Lucid Diagnostics Inc.

Form Type: 424B5

Filing Date: 2025-04-10

Corporate Action: Ipo

Type: New

Accession Number: 000164117225003664

Filing Summary: Lucid Diagnostics Inc. is offering 12,500,000 shares of its common stock under a prospectus supplement filed pursuant to Rule 424(b)(5), with a total offering price of $15,000,000 at a per-share price of $1.20. The underwriting discount amounts to $892,500, providing net proceeds of approximately $14,107,500 before expenses. The underwriters possess an option to purchase up to 1,875,000 additional shares within 45 days. The common stock is traded on the Nasdaq under the symbol 'LUCD'. As of April 8, 2025, the last reported price of the common stock was $1.62 per share. Proceeds will be utilized for working capital and other corporate purposes. The company has secured commitments for coverage under Medicare for its EsoGuard test, a diagnostic aimed at early detection of esophageal precancer. The offering's delivery is expected around April 11, 2025, managed by Canaccord Genuity and Maxim Group LLC. This prospectus supplement presents vital data concerning the offering, including risk factors, use of proceeds, and underwriter information, crucial for potential investors.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-04-10

Corporate Action: Ipo

Type: New

Accession Number: 000164117225003526

Filing Summary: On April 9, 2025, Lucid Diagnostics Inc. entered into an underwriting agreement with Canaccord Genuity LLC for an underwritten public offering of shares of common stock at a public offering price of $1.20 per share. The Company plans to sell 12,500,000 shares at an underwriting price of $1.1286 per share, with a total estimated gross proceeds of approximately $15 million, and up to $17.25 million if an additional 1,875,000 shares are purchased through an option grant to the underwriters. The offering is set to close around April 11, 2025, pending customary conditions. This offering utilizes an existing shelf registration statement filed with the SEC in November 2022. Press releases regarding the offering and its pricing were also issued on the same day, April 9, 2025.

Document Link: View Document

Form Type: 424B5

Filing Date: 2025-03-05

Corporate Action: Ipo

Type: New

Accession Number: 000149315225009096

Filing Summary: Lucid Diagnostics Inc. is initiating a public offering of up to 13,939,331 shares of its common stock at a price of $1.10 per share. The offering, filed under Rule 424(b)(5), is conducted through Canaccord Genuity LLC as the exclusive placement agent, which will use its best efforts to arrange the sale of these shares. The expected proceeds from the offering, before expenses, amount to $14,934,726. The prospectus supplement provides critical information including market value and risk factors associated with the investment in its securities. As of the latest sale on March 3, 2025, the company’s stock was priced at $1.34. Significant retrospective data was also presented supporting the value of its flagship product, the EsoGuard Esophageal DNA Test, aimed at early detection of esophageal precancer. Further details include coverage considerations by Medicare and the termination of an at-the-market program effective March 4, 2025.

Document Link: View Document